SelectQuote, Inc.

NYSE:SLQT 株式レポート

時価総額:US$209.9m

SelectQuote 将来の成長

Future 基準チェック /06

SelectQuoteの収益は年間183.4%で減少すると予測されていますが、年間収益は年間5%で増加すると予想されています。EPS は年間182.9%で減少すると予想されています。

主要情報

-183.4%

収益成長率

-182.89%

EPS成長率

Insurance 収益成長1.8%
収益成長率5.0%
将来の株主資本利益率n/a
アナリストカバレッジ

Low

最終更新日14 May 2026

今後の成長に関する最新情報

Recent updates

ナラティブの更新 May 04

SLQT: Reset Assumptions And Profit Margin Focus Will Support Future Upside Potential

SelectQuote’s updated analyst price target has moved to $5.00. Analysts cite adjustments to discount rates, revenue growth assumptions, profit margin expectations, and a revised future P/E of 5.76 as key drivers of the change.
ナラティブの更新 Apr 20

SLQT: Local Franchise Expansion Will Support Future P/E Re Rating

Analysts have trimmed their price targets on SelectQuote by $1 to $2, citing updated views on discount rates, revenue growth, profit margins, and future P/E assumptions as the drivers of this shift. Analyst Commentary Bearish analysts cutting price targets by $1 to $2 are signaling that they see less room for upside in SelectQuote at current levels.
ナラティブの更新 Apr 06

SLQT: Reset Expectations And Pharmacy Agreement Will Support Future Upside

Analysts trimmed their SelectQuote price targets by $1 to $2, citing updated assumptions around discount rates, profit margins and long term P/E expectations that indicate a more cautious outlook on the shares. Analyst Commentary Recent research updates point to a more measured stance on SelectQuote, with price targets trimmed by $1 to $2 as analysts revisit their assumptions around discount rates, profit margins and long term P/E levels.
ナラティブの更新 Mar 22

SLQT: Pharmacy Agreement And Local Expansion Will Support Future P/E Re Rating

Analysts have trimmed their price targets on SelectQuote, with recent Street research indicating cuts of $1 and $2 to reflect revised assumptions around fair value, required return, growth and future P/E expectations. Analyst Commentary Recent Street research highlights a more cautious tone around SelectQuote, with bearish analysts trimming price targets by $1 and $2 to align with their updated assumptions on fair value, required return, growth and future P/E expectations.
ナラティブの更新 Mar 07

SLQT: Reset Expectations And New Pharmacy Agreement Will Support Future Upside

Narrative Update on SelectQuote The consensus analyst price target for SelectQuote has been reduced by a few dollars as analysts reassess their models following recent cuts of $1 and $2 highlighted in new Street research. Analyst Commentary Recent research highlights that the revised price targets reflect updated views on SelectQuote's execution risks and potential for improvement, rather than a complete shift in sentiment.
ナラティブの更新 Feb 21

SLQT: Rebased Expectations And New Pharmacy Agreement Will Support Future Upside

Analysts have trimmed their price targets on SelectQuote, with recent cuts of $1 and $2 contributing to a reduction in our fair value estimate from $4.50 to about $3.06 as they factor in adjusted growth, profitability, and risk assumptions. Analyst Commentary Bullish Takeaways Bullish analysts see the revised price targets as reflecting updated expectations on growth and profitability rather than a fundamental change in the long term opportunity, which they still factor into their models.
ナラティブの更新 Feb 07

SLQT: Reset Assumptions And Pharmacy Agreement Will Support Future Upside Potential

Analysts have lowered their fair value estimate for SelectQuote from US$7.00 to US$5.00. This change reflects updated assumptions around higher discount rates, more modest revenue growth, slimmer profit margins and a higher future P/E multiple.
分析記事 Feb 06

SelectQuote, Inc. (NYSE:SLQT) Stock's 27% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Unfortunately for some shareholders, the SelectQuote, Inc. ( NYSE:SLQT ) share price has dived 27% in the last thirty...
Seeking Alpha Feb 01

SelectQuote Q2 Earnings Preview: Sell The Medicare Reimbursement News (Rating Downgrade)

Summary SelectQuote is downgraded to sell as Medicare Advantage reimbursement shocks threaten its core business model. SLQT’s fundamentals are deteriorating, with Senior segment profitability slipping and commission revenue at risk from insurer belt-tightening. The 2027 Medicare reimbursement rate increase of just 0.09% is far below expectations, likely pressuring insurer and broker margins. Despite low EBITDA multiples, SLQT’s reliance on insurer commissions and worsening industry outlook justify caution ahead of Q2 earnings. Read the full article on Seeking Alpha
ナラティブの更新 Jan 23

SLQT: Future Pharmacy Agreement Will Likely Support P/E Re Rating

Analysts have trimmed their price target on SelectQuote to US$2.00 from US$2.00, citing updated assumptions for discount rate, revenue growth, profit margin and future P/E. Together these factors point to a slightly adjusted risk and earnings profile without changing the headline fair value figure.
ナラティブの更新 Jan 09

SLQT: Future Profitability Shift Will Likely Unlock Deep P/E Re Rating

Analysts have reduced their price target on SelectQuote, citing a lower fair value estimate and higher discount rate, even as updated assumptions point to a higher profit margin and a much lower future P/E multiple of about 2.1x versus 26.2x previously. Valuation Changes The Fair Value Estimate was reduced from 3.0 to 2.0, indicating a lower assessed intrinsic value per share.
ナラティブの更新 Dec 19

SLQT: Expanded Senior Support Services Will Drive Future Upside Potential

Analysts have modestly raised their price target on SelectQuote, citing a slightly higher discount rate and marginally improved long term profitability assumptions. Together, these factors support an incremental increase in estimated equity value of roughly a few cents per share.
ナラティブの更新 Dec 05

SLQT: Expanded Senior Support Partnerships Will Drive Future Upside Potential

Analysts have modestly raised their price target on SelectQuote by refining their discount rate assumptions and reaffirming steady long term revenue growth and profit margin expectations. This has resulted in an updated fair value estimate that is now closer to fundamentals, though it still implies limited upside from current levels.
ナラティブの更新 Nov 21

SLQT: Expanding Senior Referral Program Will Drive Broader Long-Term Support

Analysts have lowered their price target for SelectQuote from $5.00 to $4.50 per share. They cited changes in profit margin forecasts and a higher discount rate as key factors in the revised outlook.
分析記事 Nov 15

Investors Give SelectQuote, Inc. (NYSE:SLQT) Shares A 26% Hiding

The SelectQuote, Inc. ( NYSE:SLQT ) share price has fared very poorly over the last month, falling by a substantial...
ナラティブの更新 Nov 07

SLQT: Expanded Senior Services Will Unlock Long-Term Upside Despite Legal Risks

SelectQuote Price Target Lowered Amid Revised Analyst Outlook Analysts have reduced SelectQuote's price target from $5.25 to $5.00, citing updated forecasts of slower revenue growth and reduced profit margins. What's in the News SelectQuote announced a milestone partnership with Findhelp, which will enable the company to direct over 200,000 low-income seniors to free and discounted social services such as food assistance, housing aid, transportation, healthcare, and financial or legal counseling (Key Developments).
分析記事 Aug 31

SelectQuote, Inc. (NYSE:SLQT) Stock Rockets 30% But Many Are Still Ignoring The Company

SelectQuote, Inc. ( NYSE:SLQT ) shares have had a really impressive month, gaining 30% after a shaky period beforehand...
分析記事 Jul 16

SelectQuote, Inc. (NYSE:SLQT) Could Be Riskier Than It Looks

When close to half the companies operating in the Insurance industry in the United States have price-to-sales ratios...
Seeking Alpha Apr 28

SelectQuote: Better Fundamentals Due To Medicare Advantage Reimbursement Rate Increase (Rating Upgrade)

Summary I'm upgrading SelectQuote to a buy rating after the stock's recent sharp fall. The federal government recently approved a 5.06% reimbursement rate increase for Medicare Advantage plans, which should translate into more aggressive marketing from carriers. This will lead to stronger demand and referral fees for SelectQuote, similar to how the government's premium increase approvals helped EverQuote in the auto insurance industry. SelectQuote is a value stock at <8x forward adjusted EBITDA. Read the full article on Seeking Alpha
User avatar
新しいナラティブ Mar 26

Agent Efficiency And Medicare Services Will Transform 2025 Outlook

Improved agent efficiency and optimized marketing reduced expenses, boosting productivity and potentially enhancing margins and earnings.
Seeking Alpha Feb 11

SelectQuote: Better Prospects After Bain Deal, But Don't Rush To Buy (Upgrade)

Summary SelectQuote, Inc. skyrocketed ~30% after posting very strong Q2 results alongside the announcement of a $350 million private infusion from investors led by Bain Capital. Revenue grew 19% year-over-year to $481.1 million, with the Senior division and Health Services arm showing notable improvements in efficiency and subscriber growth. Despite a $350 million investment to reduce debt, SelectQuote remains highly leveraged, and SLQT stock's valuation is not compelling enough to warrant a bullish stance. I'd need to see a turnaround in profitability for the SelectRx division (better than the ~1% adjusted EBITDA margins seen in Q2) to consider buying SLQT stock. Read the full article on Seeking Alpha
分析記事 Jan 18

SelectQuote, Inc. (NYSE:SLQT) Soars 36% But It's A Story Of Risk Vs Reward

Despite an already strong run, SelectQuote, Inc. ( NYSE:SLQT ) shares have been powering on, with a gain of 36% in the...
分析記事 Nov 20

SelectQuote, Inc. (NYSE:SLQT) Stock Rockets 29% But Many Are Still Ignoring The Company

Those holding SelectQuote, Inc. ( NYSE:SLQT ) shares would be relieved that the share price has rebounded 29% in the...
分析記事 Nov 07

SelectQuote, Inc. (NYSE:SLQT) Released Earnings Last Week And Analysts Lifted Their Price Target To US$4.50

It's been a pretty great week for SelectQuote, Inc. ( NYSE:SLQT ) shareholders, with its shares surging 17% to US$2.34...
分析記事 Oct 03

SelectQuote, Inc. (NYSE:SLQT) Might Not Be As Mispriced As It Looks After Plunging 49%

SelectQuote, Inc. ( NYSE:SLQT ) shares have had a horrible month, losing 49% after a relatively good period beforehand...
分析記事 Jul 02

SelectQuote, Inc. (NYSE:SLQT) Doing What It Can To Lift Shares

When you see that almost half of the companies in the Insurance industry in the United States have price-to-sales...
分析記事 Feb 13

Investors Still Aren't Entirely Convinced By SelectQuote, Inc.'s (NYSE:SLQT) Revenues Despite 29% Price Jump

SelectQuote, Inc. ( NYSE:SLQT ) shares have had a really impressive month, gaining 29% after a shaky period beforehand...
Seeking Alpha Feb 07

SelectQuote Q2: Strong Revenue Growth But Retaining My Hold Rating

Summary SelectQuote, Inc.'s fiscal Q2 revenue of $405.44 million beat estimates, marking the 6th consecutive quarter of increasing YoY revenue. The company raised its revenue guidance for FY 2024 to $1.23 billion to $1.3 billion, a 17% increase from the prior low-end guidance. Despite positive revenue growth, SelectQuote is still losing money and has a significant long-term debt load of $650 million. Read the full article on Seeking Alpha
Seeking Alpha Nov 13

SelectQuote: Insider Buying But A Significant Debt Load

Summary SelectQuote, Inc. is a small-cap online insurance broker with a stock that has had a huge decline since coming public in early 2020. However, the company has made some progress in reducing costs and the shares saw some significant insider purchases in May and September of this year. Time to buy into this improving story?  An analysis follows in the paragraphs below. Read the full article on Seeking Alpha
分析記事 Nov 08

It's Probably Less Likely That SelectQuote, Inc.'s (NYSE:SLQT) CEO Will See A Huge Pay Rise This Year

Key Insights SelectQuote to hold its Annual General Meeting on 14th of November Total pay for CEO Tim Danker includes...

業績と収益の成長予測

NYSE:SLQT - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
6/30/20271,743-21N/A664
6/30/20261,650-5N/A304
3/31/20261,64221-17-2N/A
12/31/20251,61920-212N/A
9/30/20251,56322-29-17N/A
6/30/20251,52725-23-12N/A
3/31/20251,489-23546N/A
12/31/20241,457-14919N/A
9/30/20241,381-481022N/A
6/30/20241,322-34415N/A
3/31/20241,236-51-23-11N/A
12/31/20231,159-50-47N/A
9/30/20231,073-47-54N/A
6/30/20231,003-59-29-19N/A
3/31/2023920-115-76-67N/A
12/31/2022895-132-124-108N/A
9/30/2022770-292-325-298N/A
6/30/2022764-298-373-338N/A
3/31/2022809-193-382-339N/A
12/31/2021800-151-355-318N/A
9/30/202196377-223-193N/A
6/30/2021930125-138-115N/A
3/31/2021887143-98-81N/A
12/31/2020770129-131-114N/A
9/30/2020589-12-75-59N/A
6/30/2020529-18-77-62N/A
3/31/2020464-25-58-46N/A
12/31/2019403-26N/A-38N/A
9/30/201931540N/A-5N/A
6/30/201933760N/A0N/A
6/30/201823422N/A-5N/A

アナリストによる今後の成長予測

収入対貯蓄率: SLQTの収益は今後 3 年間で減少すると予測されています (年間-183.4% )。

収益対市場: SLQTの収益は今後 3 年間で減少すると予測されています (年間-183.4% )。

高成長収益: SLQTの収益は今後 3 年間で減少すると予測されています。

収益対市場: SLQTの収益 ( 5% ) US市場 ( 11.7% ) よりも低い成長が予測されています。

高い収益成長: SLQTの収益 ( 5% ) 20%よりも低い成長が予測されています。


一株当たり利益成長率予想


将来の株主資本利益率

将来のROE: SLQTの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です


成長企業の発掘

企業分析と財務データの現状

データ最終更新日(UTC時間)
企業分析2026/05/15 14:58
終値2026/05/14 00:00
収益2026/03/31
年間収益2025/06/30

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM(Trailing Twelve Month)またはLTM(Last Twelve Month)データとして知られています。詳細はこちら

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

SelectQuote, Inc. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。12

アナリスト機関
Steven ValiquetteBarclays
Steven ValiquetteBarclays
Daniel GrosslightCitigroup Inc